A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2016
Price : $35 *
At a glance
- Drugs GSK 598809 (Primary)
- Indications Smoking withdrawal; Substance-related disorders
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Feb 2016 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 28 Oct 2014 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov record.
- 15 May 2014 New trial record